{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhou X"],"funding":["Science and Technology Commission of Shanghai Municipality","shanghai general hospital","Shanghai Municipal Health and Family Planning Commission","Shanghai Municipal Education Commission","National Clinical Research Center for Hematologic Disease","Shanghai Shen Kang Hospital Development Center","Shanghai General Hospital"],"pagination":["9636897221079739"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8894976"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31"],"pubmed_abstract":["Standard anti-thymocyte globulin (ATG) weight-based dosing often resulted in highly variable ATG exposure, which had profound effects on relapse and survival, especially in recipients with relatively low absolute lymphocyte count (ALC) before conditioning. Data regarding rabbit ATG pharmacokinetics and pharmacodynamics in the setting of HLA-haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) is lacking. We conducted a retrospective study on 90 consecutive patients who underwent haplo-PBSCT with low dose rabbit ATG (5 mg/kg) plus low dose post-transplant cyclophosphamide (50 mg/kg) based regimen for graft-versus-host disease (GvHD) prophylaxis. We compared serum concentration of ATG and post-transplant results between patients with ALC<500/μl and ALC≥500/μl before condit"],"journal":["Cell transplantation"],"pubmed_title":["Lower Absolute Lymphocyte Count Before Conditioning Predicts High Relapse Risk in Patients After Haploidentical Peripheral Blood Stem Cell Transplantation With Low Dose Anti-Thymocyte Globulin/Post-Transplant Cyclophosphamide for GvHD Prophylaxis."],"pmcid":["PMC8894976"],"funding_grant_id":["Clinical Research Innovation Plan","SHDC12018X09","201840043","CTCCR-2018B02","18411968400","SHDC2020CR3028B","CTCCR-2018BP03","Gaofeng Clinical Medicine 20181811","SHDC2020CR1012B","16CR1010A","2020ZKPC02"],"pubmed_authors":["Xia X","Yang J","Huang C","Qiu H","Wan L","Shen C","Tong Y","Zhou X","Wei Y","Zhang Y","Niu J","Cai Y","Xu X","Song X","Zhou K"],"additional_accession":[]},"is_claimable":false,"name":"Lower Absolute Lymphocyte Count Before Conditioning Predicts High Relapse Risk in Patients After Haploidentical Peripheral Blood Stem Cell Transplantation With Low Dose Anti-Thymocyte Globulin/Post-Transplant Cyclophosphamide for GvHD Prophylaxis.","description":"Standard anti-thymocyte globulin (ATG) weight-based dosing often resulted in highly variable ATG exposure, which had profound effects on relapse and survival, especially in recipients with relatively low absolute lymphocyte count (ALC) before conditioning. Data regarding rabbit ATG pharmacokinetics and pharmacodynamics in the setting of HLA-haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) is lacking. We conducted a retrospective study on 90 consecutive patients who underwent haplo-PBSCT with low dose rabbit ATG (5 mg/kg) plus low dose post-transplant cyclophosphamide (50 mg/kg) based regimen for graft-versus-host disease (GvHD) prophylaxis. We compared serum concentration of ATG and post-transplant results between patients with ALC<500/μl and ALC≥500/μl before condit","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan-Dec","modification":"2025-04-04T14:58:15.646Z","creation":"2025-04-04T14:58:15.646Z"},"accession":"S-EPMC8894976","cross_references":{"pubmed":["35225024"],"doi":["10.1177/09636897221079739"]}}